BioSpace News Archive

Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, efficacy, and feasibility of our seven-day vein-to-vein, point-of-care manufactured BCMA CAR-T candidate, GLPG5301, in adult patients with relapsed/refractory multiple myeloma (rrMM).

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced several corporate updates.

Illumina, Inc. announced that its executives will be speaking at the following investor conference.

Syndax Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 12,432,431 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,621,621 additional shares.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Pasithea Therapeutics Corp., announced that it held its annual meeting of stockholders on December 19, 2023.

InxMed and Escugen announced that InxMed licensed EZWi-Fit® linker-payload platform from Escugen for the development of the next generation tumor-associated antigens targeting ADCs.

Cenna Biosciences announced the appointment of David H. Crean to the Cenna Board of Directors effective Dec. 12, 2023.

MAIA Biotechnology, Inc. today announced dose selection for THIO-101, a Phase 2 clinical trial evaluating its lead asset, THIO, in sequential combination with Regeneron’s anti-PD-1 cemiplimab (Libtayo ® ).

Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen’s product TECFIDERA® (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.